Cytochrome P450-mediated hepatic metabolism of new fluorescent substrates in cats and dogs

Journal of Veterinary Pharmacology and Therapeutics

Volumn 33, Issue 6, 2010, Pages 519-527

  Van Beusekom, C D ^a   Schipper, L ^a   Fink Gremmels, J ^a  

^a UTRECHT UNIVERSITY   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

3 [2 (N,N DIETHYL N METHYLAMINO)ETHYL] 7 METHOXY 4 METHYLCOUMARIN; 7 ETHOXY 4 TRIFLUOROMETHYLCOUMARIN; 7 METHOXY 4 TRIFLUOROMETHYLCOUMARIN; ALPHA NAPHTHOFLAVONE; CYTOCHROME P450; CYTOCHROME P450 1A; CYTOCHROME P450 2B; CYTOCHROME P450 2C; CYTOCHROME P450 2D; CYTOCHROME P450 2E1; CYTOCHROME P450 3A; DIBENZYLFLUORESCEIN; DIETHYLDITHIOCARBAMIC ACID; ENZYME INHIBITOR; FLUORESCEIN; FURAFYLLINE; KETOCONAZOLE; QUERCETIN; QUINIDINE; SULFAPHENAZOLE; TRANYLCYPROMINE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ARTICLE; BIOTRANSFORMATION; CAT; CONTROLLED STUDY; DOG; DRUG METABOLISM; ENZYME ACTIVITY; ENZYME INHIBITION; ENZYME MECHANISM; ENZYME SPECIFICITY; ENZYME SUBSTRATE; FEMALE; IC 50; LIVER MICROSOME METABOLISM; MALE; NONHUMAN; OXIDATION; PRIORITY JOURNAL; SEX DIFFERENCE; SPECIES DIFFERENCE;

ANIMALS; CATS; CYTOCHROME P-450 ENZYME SYSTEM; DOGS; FEMALE; FLUORESCENT DYES; FLUOROMETRY; HUMANS; MALE; MICROSOMES, LIVER; SEX FACTORS;

CANIS FAMILIARIS; FELIDAE;

EID: 78349260127     PISSN: 01407783     EISSN: 13652885     Source Type: Journal    
DOI: 10.1111/j.1365-2885.2010.01199.x     Document Type: Article

References (42)

1. Anzenbacher, P. & Anzenbacherova, E. (2001) Cytochromes P450 and metabolism of xenobiotics. Cellular and Molecular Life Sciences, 58, 737-747.
2. Baririan, N., Desager, J.P., Petit, M. & Horsmans, Y. (2006) CYP3A4 activity in four different animal species liver microsomes using 7-benzyloxyquinoline and HPLC/spectrofluorometric determination. Journal of Pharmaceutical and Biomedical Analysis, 40, 211-214.
3. Bogaards, J.J., Bertrand, M., Jackson, P., Oudshoorn, M.J., Weaver, R.J., Van Bladeren, P.J. & Walther, B. (2000) Determining the best animal model for human cytochrome P450 activities: a comparison of mouse, rat, rabbit, dog, micropig, monkey and man. Xenobiotica, 30, 1131-1152.
4. Brosen, K. & Rasmussen, B.B. (1997) Drug interactions on the level of cytochrome P450: pharmacokinetic, pharmacogenetic and clinical aspects. Biological Psychiatry, 42, 127.
5. Buters, J.T., Schiller, C.D. & Chou, R.C. (1993) A highly sensitive tool for the assay of cytochrome P450 enzyme activity in rat, dog and man. Direct fluorescence monitoring of the deethylation of 7-ethoxy-4-trifluoromethylcoumarin. Biochemical Pharmacology, 46, 1577-1584.
6. Chauret, N., Gauthier, A., Martin, J. & Nicoll-Griffith, D.A. (1997) In vitro comparison of cytochrome P450-mediated metabolic activities in human, dog, cat, and horse. Drug Metabolism and Disposition, 25, 1130-1136.
7. Court, M.H. & Greenblatt, D.J. (1997) Molecular basis for deficient acetaminophen glucuronidation in cats. An interspecies comparison of enzyme kinetics in liver microsomes. Biochemical Pharmacology, 53, 1041-1047.
8. Court, M.H. & Greenblatt, D.J. (2000) Molecular genetic basis for deficient acetaminophen glucuronidation by cats: UGT1A6 is a pseudogene, and evidence for reduced diversity of expressed hepatic UGT1A isoforms. Pharmacogenetics, 10, 355-369.
9. Crespi, C.L. & Stresser, D.M. (2000) Fluorometric screening for metabolism-based drug--drug interactions. Journal of Pharmacological and Toxicological Methods, 44, 325-331.
10. Crespi, C.L., Miller, V.P. & Penman, B.W. (1997) Microtiter Plate Assays for Inhibition of Human, Drug-Metabolizing Cytochromes P450. Analytical Biochemistry, 248, 188-190.
11. Donato, M.T., Jimenez, N., Castell, J.V. & Gomez-Lechon, M.J. (2004) Fluorescence-based assays for screening nine cytochrome P450 (P450) activities in intact cells expressing individual human P450 enzymes. Drug Metabolism and Disposition, 32, 699-706.
12. Eagling, V.A. et al. (1998) Differential selectivity of cytochrome P450 inhibitors against probe substrates in human and rat liver microsomes. British Journal of Clinical Pharmacology, 45, 107-114.
13. Fink-Gremmels, J. (2008) Implications of hepatic cytochrome P450-related biotransformation processes in veterinary sciences. European Journal of Pharmacology, 585, 502-509.
14. Fukuda, T., Nishida, Y., Imaoka, S., Hiroi, T., Naohara, M., Funae, Y. & Azuma, J. (2000) The decreased in vivo clearance of CYP2D6 substrates by CYP2D6*10 might be caused not only by the low-expression but also by low affinity of CYP2D6. Archives of Biochemistry and Biophysics, 380, 303-308.
15. Gruenke, L.D., Konopka, K., Koop, D.R. & Waskell, L.A. (1988) Characterization of halothane oxidation by hepatic microsomes and purified cytochromes P-450 using a gas chromatographic mass spectrometric assay. Journal of Pharmacology and Experimental Therapeutics, 246, 454-459.
16. Heim, M.H. & Meyer, U.A. (1992) Evolution of a highly polymorphic human cytochrome P450 gene cluster: CYP2D6. Genomics, 14, 49-58.
17. Ingelman-Sundberg, M. (2004) Human drug metabolising cytochrome P450 enzymes: properties and polymorphisms. Naunyn Schmiedebergs Archives of Pharmacology, 369, 89-104.
18. Kharasch, E.D. & Thummel, K.E. (1993) Identification of cytochrome P450 2E1 as the predominant enzyme catalyzing human liver microsomal defluorination of sevoflurane, isoflurane, and methoxyflurane. Anesthesiology, 79, 795-807.
19. Kuroha, M., Kuze, Y., Shimoda, M. & Kokue, E. (2002) In vitro characterization of the inhibitory effects of ketoconazole on metabolic activities of cytochrome P-450 in canine hepatic microsomes. American Journal of Veterinary Research, 63, 900-905.
20. Lowry, O.H., Rosebrough, N.J., Lewis Farr, A. & Randall, R.J. (1951) Protein measurement with the Folin phenol reagent. Journal of Biological Chemistry, 193, 265-275.
21. Lu, P., Singh, S.B. & Carr, B.A. (2005) Selective inhibition of dog hepatic CYP2B11 and CYP3A12. Journal of Pharmacology and Experimental Therapeutics, 313, 518-528.
22. Maugras, M. & Reichart, E. (1979) The hepatic cytochrome level in the cat (Felis catus): normal value and variations in relation to some biological parameters. Comparative Biochemistry and Physiology B, 64, 125-127.
23. Miller, V.P., Stresser, D.M., Blanchard, A.P., Turner, S. & Crespi, C.L. (2000) Fluorometric high-throughput screening for inhibitors of cytochrome P450. Annals of the New York Academy of Sciences, 919, 26-32.
24. Morgan, E.T., Koop, D.R. & Coon, M.J. (1983) Comparison of six rabbit liver cytochrome P-450 isozymes in formation of a reactive metabolite of acetaminophen. Biochemical and Biophysical Research Communications, 112, 8-13.
25. Naritomi, Y., Teramura, Y., Terashita, S. & Kagayama, A. (2004) Utility of microtiter plate assays for human cytochrome P450 inhibition studies in drug discovery: application of simple method for detecting quasi-irreversible and irreversible inhibitors. Drug Metabolism and Pharmacokinetics, 19, 55-61.
26. Nebbia, C., Dacasto, M., Rossetto Giaccherino, A., Giuliano Albo, A. & Carletti, M. (2003) Comparative expression of liver cytochrome P450-dependent monooxygenases in the horse and in other agricultural and laboratory species. Veterinary Journal, 165, 53-64.
27. Nebert, D.W. & Russell, D.W. (2002) Clinical importance of the cytochromes P450. The Lancet, 360, 1155-1162.
28. Newton, D.J., Wang, R.W. & Lu, A.Y. (1995) Cytochrome P450 inhibitors. Evaluation of specificities in the in vitro metabolism of therapeutic agents by human liver microsomes. Drug Metabolism and Disposition, 23, 154-158.
29. Roussel, F., Duignan, D.B., Lawton, M.P., Obach, R.S., Strick, C.A. & Tweedie, D.J. (1998) Expression and characterization of canine cytochrome P450 2D15. Archives of Biochemistry and Biophysics, 357, 27-36.
30. Rutten, A.A., Falke, H.E., Catsburg, J.F., Topp, R., Blaauboer, B.J., Van Holsteijn, I., Doorn, L. & Van Leeuwen, F.X. (1987) Interlaboratory comparison of total cytochrome P-450 and protein determinations in rat liver microsomes. Reinvestigation of assay conditions. Archives of Toxicology, 61, 27-33.
31. Shah, S.S., Sanda, S., Regmi, N.L., Sasaki, K. & Shimoda, M. (2007) Characterization of cytochrome P450-mediated drug metabolism in cats. Journal of Veterinary Pharmacology and Therapeutics, 30, 422-428.
32. Sharer, J.E., Shipley, L.A., Vandenbranden, M.R., Binkley, S.N. & Wrighton, S.A. (1995) Comparisons of phase I and phase II in vitro hepatic enzyme activities of human, dog, rhesus monkey, and cynomolgus monkey. Drug Metabolism and Disposition, 23, 1231-1241.
33. Shimada, T., Mimura, M., Inoue, K., Nakamura, S., Oda, H., Ohmori, S. & Yamazaki, H. (1997) Cytochrome P450-dependent drug oxidation activities in liver microsomes of various animal species including rats, guinea pigs, dogs, monkeys, and humans. Archives of Toxicology, 71, 401-408.
34. Shou, M., Norcross, R., Sandig, G., Lu, P., Li, Y., Lin, Y., Mei, Q., Rodrigues, A.D. & Rushmore, T.H. (2003) Substrate specificity and kinetic properties of seven heterologously expressed dog cytochromes p450. Drug Metabolism and Disposition, 31, 1161-1169.
35. Stresser, D.M., Turner, S.D., Blanchard, A.P., Miller, V.P. & Crespi, C.L. (2002) Cytochrome P450 fluorometric substrates: identification of isoform-selective probes for rat CYP2D2 and human CYP3A4. Drug Metabolism and Disposition, 30, 845-852.
36. Tanaka, N., Shinkyo, R., Sakaki, T., Kasamastu, M., Imaoka, S., Funae, Y. & Yokota, H. (2005) Cytochrome P450 2E polymorphism in feline liver. Biochimica et Biophysica Acta, 1726, 194-205.
37. Tomlinson, E.S., Maggs, J.L., Park, B.K. & Back, D.J. (1997) Dexamethasone metabolism in vitro: species differences. Journal of Steroid Biochemistry and Molecular Biology, 62, 345-352.
38. Trepanier, L.A. (2006) Cytochrome P450 and its role in veterinary drug interactions. Veterinary Clinics of North America Small Animal Practice, 36, 975-985.
39. Zhao, X.J. & Ishizaki, T. (1997) The In vitro hepatic metabolism of quinine in mice, rats and dogs: comparison with human liver microsomes. Journal of Pharmacology and Experimental Therapeutics, 283, 1168-1176.
40. Zhou, S.F., Liu, J.P. & Chowbay, B. (2009) Polymorphism of human cytochrome P450 2D6 and its clinical significance: part I. Clinical Pharmacokinetics, 48, 689-723.
41. Zhou, S.F., et al. (2009) Polymorphism of human cytochrome P450 enzymes and its clinical impact. Drug Metabolism Reviews, 41, 89-295.
42. Zuber, R., Anzenbacherova, E. & Anzenbacher, P. (2002) Cytochromes P450 and experimental models of drug metabolism. Journal of Cellular and Molecular Medicine, 6, 189-198.